Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAIL: Mebendazole plus low-dose cytarabine in elderly relapsed/refractory AML
2024-518363-36-00Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mebendazole in acute myeloid leukemia (AML), sponsored by University Medical Center Hamburg-Eppendorf. Started Oct 2024; status: completed.
02
Drugs
mebendazole
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-518363-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518363-36-00.